{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:28:56Z","timestamp":1782955736352,"version":"3.54.5"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:p>Background. Despite the dramatic pertussis decrease since the licensure of whole-cell pertussis (diphtheria-tetanus toxoids-pertussis [DTP]) vaccines in the middle 1940s, pertussis remains endemic in the United States and can cause illness among persons at any age; &amp;gt;11000 pertussis cases were reported in 2003. Since July 1996, in addition to 2 DTP vaccines already in use, 5 acellular pertussis (diphtheria-tetanus toxoids-acellular pertussis [DTaP]) vaccines were licensed for use among infants; 3 DTaP vaccines were distributed widely during the study period. Because of the availability of 3 DTaP and 2 DTP vaccines and the likelihood of the vaccines being used interchangeably to vaccinate children with the recommended 5-dose schedule, measuring the effectiveness of the pertussis vaccines was a high priority.<\/jats:p>\n               <jats:p>Objective. To measure the pertussis vaccine effectiveness (VE) among US children 6 to 59 months of age.<\/jats:p>\n               <jats:p>Design. We conducted a case-control study in the Cincinnati, Ohio, metropolitan area, Colorado, Idaho, and Minnesota.<\/jats:p>\n               <jats:p>Participants. Confirmed pertussis cases among children 6 to 59 months of age at the time of disease onset, with onset in 1998\u20132001, were included. For each case subject, 5 control children were matched from birth certificate records, according to the date of birth and residence.<\/jats:p>\n               <jats:p>Outcome Measures. A standardized questionnaire was used to obtain vaccination data from parents and providers. Parents\/guardians were asked about demographic characteristics, child care attendance, the number of household members who stayed at the same home as the enrolled child for \u22652 nights per week, and cough illness of \u22652-week duration among these household members in the month before the case patient's cough onset. Pertussis vaccine doses among case children were counted as valid if they were received \u226514 days before the cough onset date (\u201cvalid period\u201d). The age of the case patient (in days) at the end of the valid period was determined, and doses of vaccine for the matched control subjects were counted as valid if they were received by that age. Conditional logistic regression models were used to estimate the matched odds ratios (ORs) for pertussis according to the number of pertussis vaccine doses. The VE was calculated with the following formula: (1 \u2212 OR) \u00d7 100. Because the pertussis antigen components or amounts differed according to vaccine, the VE of 3 or 4 doses of DTP and\/or DTaP was estimated according to the recorded vaccine manufacturer and vaccine type.<\/jats:p>\n               <jats:p>Results. All enrolled children (184 case subjects and 893 control subjects) had their vaccine history verified. The proportions of children who received 0, 1 or 2, 3, and \u22654 pertussis (DTP and\/or DTaP) vaccine doses among case subjects were 26%, 14%, 26%, and 34% and among control subjects were 2%, 8%, 33%, and 57%, respectively. Compared with 0 doses, the unadjusted VE estimate for 1 or 2 pertussis doses was 83.6% (95% confidence interval [CI]: 61.1\u201393.1%), that for 3 doses was 95.6% (95% CI: 89.7\u201398.0%), and for \u22654 doses was 97.7% (95% CI: 94.7\u201399.0%). Among children who received 4 pertussis vaccinations, the risk of pertussis was slightly higher among those who received only 1 type of vaccine (either 4 DTP doses or 4 DTaP doses), compared with those who received a combination of DTP for doses 1 to 3 and DTaP for dose 4 (OR: 2.4; 95% CI: 1.1\u20135.2). Among children who received 3 or 4 DTaP vaccine doses, the risk of pertussis was slightly higher among those who received a DTaP vaccine with 4 pertussis antigen components (a vaccine no longer available), compared with those who received the DTaP vaccine with 2 pertussis antigen components (OR: 2.5; 95% CI: 1.1\u20135.8). Among children who received 4 doses, the risk of pertussis was 2.7 times higher for children who received dose 4 early (age of \u226413 months), compared with children who received dose 4 at an older age (age of \u226514 months) (95% CI: 1.1\u20136.8). For children 6 to 23 months of age, features of household structure were significant risk factors for pertussis. In a multivariate model, compared with living with an older parent (\u226525 years of age), not living with an \u201cother\u201d household member (a relative other than a parent or sibling or a nonrelated person), and not living with a sibling 6 to 11 years of age, the risk of pertussis for children 6 to 23 months of age was 6.8 times higher if they lived with a young parent (\u226424 years of age) (95% CI: 3.1\u201315.0), 2.5 times higher if they lived with an \u201cother\u201d household member (95% CI: 1.2\u20135.4), and 2.2 times higher if they lived with a sibling 6 to 11 years of age (95% CI: 1.2\u20134.3). Adjusting for these risk factors did not change the VE. Compared with control children, case children were significantly more likely to live with a household member (representing all age groups and relationships) who reported a recent cough illness with duration of \u22652 weeks (87 [52%] of 168 case subjects, compared with 79 [8%] of 860 control subjects).<\/jats:p>\n               <jats:p>Conclusions. Any combination of \u22653 DTP\/DTaP vaccine doses for children 6 to 59 months of age was highly protective against pertussis. However, there were differences according to vaccine type (DTaP or DTP) and DTaP manufacturer. Among children who received 4 pertussis vaccine doses, a combination of 3 DTP doses followed by 1 DTaP dose had a slightly higher VE than other combinations; among children who received 3 or 4 DTaP vaccine doses, 1 DTaP vaccine performed less well. The finding that pertussis dose 4 was more effective when given to children at \u226514 months of age might be confounded if health care providers were more likely to vaccinate children at 12 months of age because of a perceived risk of undervaccination and if these same children were also at higher risk for pertussis. Household members of any age group and relationship could have been the source of pertussis, and household structure was associated with risk for pertussis for children 6 to 23 months of age. In contrast to control children in the study, 26% of case children had never been vaccinated against pertussis. Unvaccinated children are at risk for pertussis and, in a community with other unvaccinated children, can lead to community-wide pertussis outbreaks. Parents need to be educated about the morbidity and mortality risks associated with Bordetella pertussis infection, and they need to be encouraged to vaccinate their children against pertussis on time and with the recommended number of vaccine doses for optimal protection.<\/jats:p>","DOI":"10.1542\/peds.2004-2759","type":"journal-article","created":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T14:55:38Z","timestamp":1122994538000},"page":"e285-e294","source":"Crossref","is-referenced-by-count":89,"title":["Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998\u20132001"],"prefix":"10.1542","volume":"116","author":[{"given":"Kristine M.","family":"Bisgard","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly L.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoling","family":"Bi","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hahn","sequence":"additional","affiliation":[{"name":"Idaho Department of Health and Welfare, Boise, Idaho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Patrick","sequence":"additional","affiliation":[{"name":"Idaho State University, Institute of Rural Health Studies, Pocatello, Idaho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary P.","family":"Glode\u0301","sequence":"additional","affiliation":[{"name":"Children's Hospital and the University of Colorado Health Sciences Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R.","family":"Ehresmann","sequence":"additional","affiliation":[{"name":"Minnesota Department of Health, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the Pertussis Investigation Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,8,1]]},"reference":[{"key":"2021121003192980500_R1","doi-asserted-by":"crossref","unstructured":"Gu\u0308ris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990\u20131996. Clin Infect Dis.\u20081999;28:1230\u20131237","DOI":"10.1086\/514776"},{"key":"2021121003192980500_R2","unstructured":"Centers for Disease Control and Prevention. Epidemiology of pertussis: United States, 1997\u20132000. MMWR Morb Mortal Wkly Rep.\u20082002;51:73\u201376"},{"key":"2021121003192980500_R3","doi-asserted-by":"crossref","unstructured":"Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J.\u20082003;22:628\u2013634","DOI":"10.1097\/01.inf.0000073266.30728.0e"},{"key":"2021121003192980500_R4","doi-asserted-by":"crossref","unstructured":"Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985\u20131988: evaluation of the completeness of national reporting. JAMA.\u20081992;267:386\u2013391","DOI":"10.1001\/jama.267.3.386"},{"key":"2021121003192980500_R5","doi-asserted-by":"crossref","unstructured":"Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995\u20131996. J Infect Dis.\u20082001;183:1353\u20131359","DOI":"10.1086\/319853"},{"key":"2021121003192980500_R6","doi-asserted-by":"crossref","unstructured":"Baughman AL, Bisgard KM, Edwards KM, et al. Levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in United States adolescents and adults: establishment of diagnostic cutoff points. Clin Diagn Lab Immunol.\u20082004;11:1045\u20131053","DOI":"10.1128\/CDLI.11.6.1045-1053.2004"},{"key":"2021121003192980500_R7","doi-asserted-by":"crossref","unstructured":"Tanaka M, Vitek C, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980\u201398. JAMA.\u20082003;290:2968\u20132975","DOI":"10.1001\/jama.290.22.2968"},{"key":"2021121003192980500_R8","doi-asserted-by":"crossref","unstructured":"Gu\u0308ris D, Strebel PM, Tachdjian R, Bardenheier B, Wharton M, Hadler SC. Effectiveness of pertussis vaccination program using the screening method, United States, 1992\u20131994. J Infect Dis.\u20081997;176:456\u2013463","DOI":"10.1086\/514064"},{"key":"2021121003192980500_R9","doi-asserted-by":"crossref","unstructured":"Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA.\u20081992;267:2745\u20132749","DOI":"10.1001\/jama.267.20.2745"},{"key":"2021121003192980500_R10","doi-asserted-by":"crossref","unstructured":"Medical Research Council. The prevention of whooping cough by vaccination. Br Med J.\u20081951;1:1463\u20131471","DOI":"10.1136\/bmj.1.4721.1463"},{"key":"2021121003192980500_R11","doi-asserted-by":"crossref","unstructured":"Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis.\u20081987;9:866\u2013883","DOI":"10.1093\/clinids\/9.5.866"},{"key":"2021121003192980500_R12","doi-asserted-by":"crossref","unstructured":"Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med.\u20081996;334:349\u2013355","DOI":"10.1056\/NEJM199602083340602"},{"key":"2021121003192980500_R13","doi-asserted-by":"crossref","unstructured":"Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med.\u20081996;334:341\u2013348","DOI":"10.1056\/NEJM199602083340601"},{"key":"2021121003192980500_R14","doi-asserted-by":"crossref","unstructured":"Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who recieved either the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics.\u20081998;101:1\u201311","DOI":"10.1542\/peds.101.1.1"},{"key":"2021121003192980500_R15","doi-asserted-by":"crossref","unstructured":"Heininger U, Cherry JD, Stehr K, et al. Comparative efficacy of the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children. Pediatrics.\u20081998;102:546\u2013553","DOI":"10.1542\/peds.102.3.546"},{"key":"2021121003192980500_R16","doi-asserted-by":"crossref","unstructured":"Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med.\u20081995;333:1045\u20131050","DOI":"10.1056\/NEJM199510193331604"},{"key":"2021121003192980500_R17","doi-asserted-by":"crossref","unstructured":"Schmitt HJ, Wirsing von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA.\u20081996;275:37\u201341","DOI":"10.1001\/jama.275.1.37"},{"key":"2021121003192980500_R18","unstructured":"Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081997;46(RR-7):1\u201325"},{"key":"2021121003192980500_R19","unstructured":"Centers for Disease Control and Prevention. Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children: United States, 2002. MMWR Morb Mortal Wkly Rep.\u20082002;51:574"},{"key":"2021121003192980500_R20","unstructured":"Council of State and Territorial Epidemiologists. 1997 position statements. Presented at the CSTE National Meeting; 1997; Saratoga Springs, NY, June 16\u201319. Position Statement 9. Available at: www.cste.org\/ps\/1997\/1997-id-09.htm. Accessed June 1, 2004"},{"key":"2021121003192980500_R21","doi-asserted-by":"crossref","unstructured":"Muller FM, Hoppe JE, Wirsing von Konig CH. Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol.\u20081997;35:2435\u20132443","DOI":"10.1128\/jcm.35.10.2435-2443.1997"},{"key":"2021121003192980500_R22","doi-asserted-by":"crossref","unstructured":"Deeks S, De Serres G, Boulianne N, et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis.\u20081999;20:840\u2013846","DOI":"10.1086\/515203"},{"key":"2021121003192980500_R23","doi-asserted-by":"crossref","unstructured":"Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J.\u20081997;16:1038\u20131044","DOI":"10.1097\/00006454-199711000-00007"},{"key":"2021121003192980500_R24","doi-asserted-by":"crossref","unstructured":"Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.Vaccine.\u20081998;16:1907\u20131916","DOI":"10.1016\/S0264-410X(98)00227-8"},{"key":"2021121003192980500_R25","doi-asserted-by":"crossref","unstructured":"Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.Vaccine.\u20082003;21:3542\u20133549","DOI":"10.1016\/S0264-410X(03)00407-9"},{"key":"2021121003192980500_R26","doi-asserted-by":"crossref","unstructured":"Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine.\u20081998;16:1901\u20131906","DOI":"10.1016\/S0264-410X(98)00226-6"},{"key":"2021121003192980500_R27","doi-asserted-by":"crossref","unstructured":"Kuno-Sakai H, Kimua M, Watanabe H. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals.\u20082004;32:29\u201335","DOI":"10.1016\/j.biologicals.2003.11.001"},{"key":"2021121003192980500_R28","unstructured":"Centers for Disease Control and Prevention. Update on the supply of tetanus and diphtheria toxoids and of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep.\u20082001;50:189\u2013190"},{"key":"2021121003192980500_R29","doi-asserted-by":"crossref","unstructured":"Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source?Pediatr Infect Dis J.\u20082004;23:985\u2013989","DOI":"10.1097\/01.inf.0000145263.37198.2b"},{"key":"2021121003192980500_R30","doi-asserted-by":"crossref","unstructured":"Halperin SA, Wang EEL, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991\u20131997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis.\u20081999;28:1238\u20131243","DOI":"10.1086\/514792"},{"key":"2021121003192980500_R31","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis.\u20081996;22:503\u2013507","DOI":"10.1093\/clinids\/22.3.503"},{"key":"2021121003192980500_R32","doi-asserted-by":"crossref","unstructured":"Biellik RJ, Patriarca PA, Mullen JR, et al. Risk factors for community- and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis.\u20081988;157:1134\u20131141","DOI":"10.1093\/infdis\/157.6.1134"},{"key":"2021121003192980500_R33","unstructured":"Centers for Disease Control and Prevention. Vaccination coverage by race\/ethnicity and poverty level among children aged 19\u201335 months: United States, 1997. MMWR Morb Mortal Wkly Rep.\u20081998;47:956\u2013959"},{"key":"2021121003192980500_R34","doi-asserted-by":"crossref","unstructured":"Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RA, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA.\u20082000;284:3145\u20133150","DOI":"10.1001\/jama.284.24.3145"},{"key":"2021121003192980500_R35","doi-asserted-by":"crossref","unstructured":"Gangarosa EJ, Galazka A, Wolfe CR, Phillips LM, Miller E, Chen RT. Impact of the anti-vaccine movements on pertussis control: the untold story. Lancet.\u20081998;351:356\u2013361","DOI":"10.1016\/S0140-6736(97)04334-1"},{"key":"2021121003192980500_R36","doi-asserted-by":"crossref","unstructured":"Juretzko P, von Kries R, Hermann M, Wirsing von Konig CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis.\u20082002;35:162\u2013167","DOI":"10.1086\/341027"},{"key":"2021121003192980500_R37","unstructured":"Centers for Disease Control and Prevention. Recommended childhood immunization schedule, January\u2013June, 2004. MMWR Morb Mortal Wkly Rep.\u20082004;53:Q1\u2013Q4"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/2\/e285\/1004469\/zpe0080500e285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/2\/e285\/1004469\/zpe0080500e285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T09:53:31Z","timestamp":1639130011000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/2\/e285\/62927\/Pertussis-Vaccine-Effectiveness-Among-Children-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,8,1]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2759","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}